Research name: Retatrutide
These data come from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 277 million patient records from 1,500 hospitals and more than 36,000 clinics from all 50 states, Lebanon, and Saudi Arabia
Key factors influencing cost include: Regulatory status: Licensed medicines that have undergone full MHRA or EMA approval typically command higher prices than older, off-patent alternatives, reflecting the investment in clinical development and post-marketing surveillance
When activated, glucagon receptors increase energy expenditure through thermogenesis, promote lipolysis, which is the breakdown of stored fat, and enhance fatty acid oxidation in the liver
Published clinical investigations involving retatrutide relate to an investigational compound evaluated under regulated research conditions and should not be interpreted as evidence supporting the use of this research product in patients
The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis
